caa a22 4500 606240462 CHVBK 20210128101308.0 cr unu---uuuuu 210128e20150301xx s 000 0 eng 10.1007/s00508-015-0748-0 doi (NATIONALLICENCE)springer-10.1007/s00508-015-0748-0 Efficacy, safety, and tolerability of antihypertensive therapy with aliskiren/amlodipine in clinical practice in Austria. The RALLY (Rasilamlo long lasting efficacy) study [Elektronische Daten] [Alexander R. Rosenkranz, Michaela Ratzinger] Summary: Aim: This observational study evaluated the efficacy and tolerability of 3-month aliskiren/amlodipine therapy under outpatient conditions. Methods: This Austria-wide observational study included 579 hypertensive patients (566 [98%] who could be analyzed biometrically) under the care of 140 physicians. The average age of the patient collective was 64±11 years and the mean duration of hypertension was 10±7 years. Regarding 92% of the study participants, an antihypertensive therapy already existed. Efficacy was assessed in accordance with the Austrian hypertension guidelines while tolerability was evaluated on the basis of adverse events. A descriptive physician judgment based on efficacy, tolerability, and compliance was available for 539 patients (95%). Office blood pressure values were used for the evaluation. Results: On average, the systolic and diastolic blood pressures were reduced from 161±14 to 135±10mmHg and 93±9 to 81±6mmHg, respectively. Blood pressure values of <140/90mmHg and <130/80mmHg were achieved in 56 and 7% patients, respectively. A subgroup analysis of 242 patients (43%) with diabetes mellitus and/or renal disease, as well as those with a high cardiovascular risk, demonstrated nearly identical results compared to the total population. Overall, 44 adverse events were documented in 41 patients, and physicians reported that 94% of patients were compliant in a final survey on evaluation of therapy. Conclusion: The fixed-dose combination of aliskiren/amlodipine provided clinically relevant blood pressure reductions along with good tolerance and compliance. During the 3-month duration of observation under outpatient conditions, it was seen that aliskiren and amlodipine reduced the systolic and diastolic blood pressures on average by 26 and 13mmHg, respectively. Springer-Verlag Wien, 2015 Hypertension nationallicence Observational study nationallicence Aliskiren/amlodipine nationallicence Fixed-dose combination therapy nationallicence Renin-angiotensin-aldosterone system (RAAS) nationallicence Rosenkranz Alexander R. Department of Internal Medicine, Clinical Division of Nephrology, Medical University of Graz, Auenbruggerplatz 27, 8036, Graz, Austria aut Ratzinger Michaela Novartis Pharma, Ltd., Vienna, Austria aut Wiener klinische Wochenschrift Springer Vienna 127/5-6(2015-03-01), 203-209 0043-5325 127:5-6<203 2015 127 508 https://doi.org/10.1007/s00508-015-0748-0 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s00508-015-0748-0 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Rosenkranz Alexander R. Department of Internal Medicine, Clinical Division of Nephrology, Medical University of Graz, Auenbruggerplatz 27, 8036, Graz, Austria aut NATIONALLICENCE 700 1- Ratzinger Michaela Novartis Pharma, Ltd., Vienna, Austria aut NATIONALLICENCE 773 0- Wiener klinische Wochenschrift Springer Vienna 127/5-6(2015-03-01), 203-209 0043-5325 127:5-6<203 2015 127 508